June 21, 2022

Merck Presents Positive Results From Phase 1/2 Study Of Pneumococcal Conjugate Vaccine

(RTTNews) – Merck & Co., Inc. (MRK) said it has presented positive results from the phase 1/2 study, dubbed as V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, in pneumococcal vaccine

This post was originally published on this site

Sign Up To Get FREE News, Tips and Offers!

X